Literature DB >> 9554483

Automated fluorescent analysis procedure for enzymatic mutation detection.

B J Del Tito1, H E Poff, M A Novotny, D M Cartledge, R I Walker, C D Earl, A L Bailey.   

Abstract

The Enzymatic Mutation Detection (EMD) assay detects mutations or polymorphisms in DNA. The assay procedure takes <1 h and is followed by electrophoretic detection. We report an automated procedure, using fluorescently labeled probe and quantitative analysis on the ABI Prism 377 DNA Sequencer, that improves on earlier methods (1, 2) by eliminating the need for sample purification, shortening the hybridization time, and increasing the signal-to-noise ratio. The EMD assay uses the bacteriophage resolvase T4 endonuclease VII, which cleaves the heteroduplex molecules at the mismatch site, forming two shorter fragments that are resolved by gel electrophoresis. Unlike existing mutation techniques, the EMD method uses a single protocol to identify point mutations, deletions, and insertions for all DNA fragments. Test DNA samples are assayed directly from PCR reactions, and fragments up to 4 kb in size have been assayed successfully. A independent analysis on the p53 tumor suppressor gene from clinical samples has shown 100% sensitivity and 94% specificity. Because the fluorescent EMD assay has been optimized for high signal-to-noise ratios, mutations can be identified in mixed samples containing up to a 20-fold excess of normal DNA.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9554483

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  7 in total

Review 1.  Automated mutation analysis.

Authors:  D Ravine
Journal:  J Inherit Metab Dis       Date:  1999-06       Impact factor: 4.982

2.  Microchip electrophoresis: a method for high-speed SNP detection.

Authors:  D Schmalzing; A Belenky; M A Novotny; L Koutny; O Salas-Solano; S El-Difrawy; A Adourian; P Matsudaira; D Ehrlich
Journal:  Nucleic Acids Res       Date:  2000-05-01       Impact factor: 16.971

3.  The use of resolvases T4 endonuclease VII and T7 endonuclease I in mutation detection.

Authors:  J J Babon; M McKenzie; R G H Cotton
Journal:  Mol Biotechnol       Date:  2003-01       Impact factor: 2.695

4.  A founding locus within the RET proto-oncogene may account for a large proportion of apparently sporadic Hirschsprung disease and a subset of cases of sporadic medullary thyroid carcinoma.

Authors:  Salud Borrego; Fred A Wright; Raquel M Fernández; Nita Williams; Manuel López-Alonso; Ramana Davuluri; Guillermo Antiñolo; Charis Eng
Journal:  Am J Hum Genet       Date:  2002-12-09       Impact factor: 11.025

5.  Oligonucleotide arrays for high-throughput SNPs detection in the MHC class I genes: HLA-B as a model system.

Authors:  Zhen Guo; Mark S Gatterman; Lee Hood; John A Hansen; Effie W Petersdorf
Journal:  Genome Res       Date:  2002-03       Impact factor: 9.043

6.  CDKN2A gene inactivation in epithelial sporadic ovarian cancer.

Authors:  D Niederacher; H Y Yan; H X An; H G Bender; M W Beckmann
Journal:  Br J Cancer       Date:  1999-08       Impact factor: 7.640

7.  Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations.

Authors:  A S Whittemore; R R Balise; P D P Pharoah; R A Dicioccio; I Oakley-Girvan; S J Ramus; M Daly; M B Usinowicz; K Garlinghouse-Jones; B A J Ponder; S Buys; R Senie; I Andrulis; E John; J L Hopper; M S Piver
Journal:  Br J Cancer       Date:  2004-11-29       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.